Timothy Mark Clay, Ph.D.

Associate Professor of Surgery

Department:
Surgery

Division:
Surgical Sciences

Email:
timclaydukeedu

Mailing Address:
Box 2606, DUMC
Durham, NC 27710

Telephone:
919-681-8350

Training:
Ph.D., Bristol Polytechnic (United Kingdom)

Last Updated:
June 04, 2009

Research Interests:
The Clay Lab is studying the immune system in cancer patients and developing cancer vaccines to generate anti-tumor immune responses that might lead to tumor eradication.  The lab is engaged in basic and translational research.  Basic research involves fundamental exploration of how the immune system responds to vaccines and tumors, and how the tumor microenvironment affects immune responses to the tumor.  Our translational research involves preclinical development of vaccine candidates leading to the testing of new cancer vaccines in human clinical trials.  This is a true “bench-to-bedside-to-bench” effort where our results in patients’ feed back into our laboratory studies and help to develop the next generation of vaccines.

Publications:
2009 -- Pubmed # 19351755 -- Osada T, Woo CY, McKinney M, Yang XY, Lei G, Labreche HG, Hartman ZC, Niedzwiecki D, Chao N, Amalfitano A, Morse MA, Lyerly HK, Clay TM. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res. 2009 Apr 15;15(8):2789-96.

2009 -- Pubmed # 19229288 -- Osada T, Yang XY, Hartman ZC, Glass O, Hodges BL, Niedzwiecki D, Morse MA, Lyerly HK, Amalfitano A, Clay TM. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther. 2009 Feb 20.

2008 -- Pubmed # 18519811 -- Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008 Aug 1;112(3):610-8.

2007 -- Pubmed # 17121790 -- Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM, Amalfitano A. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol. 2007 Feb;81(4):1796-812.

2007 -- Pubmed # 17822557 -- Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med. 2007;5:42.

2005 -- Pubmed # 15614046 -- Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.  J Immunother.  2005 Jan-Feb;28(1):63-72.

2005 -- Pubmed # 16027139 -- Osada T, Morse MA, Lyerly HK, Clay TM. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.  Int Immunol.  2005 Sep;17(9):1143-55.

2001 -- Pubmed # 11350875 -- Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer.  Clin Cancer Res.  2001 May;7(5):1127-35.

1999 -- Pubmed # 10384155 -- Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.  J Immunol.  1999 Jul 1;163(1):507-13.